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Abstract The glycine-alanine (GA) repeat of the Epstein^Barr
virus nuclear antigen-1 inhibits in cis ubiquitin-dependent pro-
teolysis in mammalian cells through a yet unknown mechanism.
In the present study we demonstrate that the GA repeat targets
an evolutionarily conserved step in proteolysis since it can pre-
vent the degradation of proteasomal substrates in the yeast
Saccharomyces cerevisiae. Insertion of yeast codon-optimised
recombinant GA (rGA) repeats of di¡erent length in green £uo-
rescent protein reporters harbouring N-end rule or ubiquitin
fusion degradation signals resulted in e⁄cient stabilisation of
these substrates. Protection was also achieved in rpn10v yeast
suggesting that this polyubiquitin binding protein is not required
for the rGA e¡ect. The conserved e¡ect of the GA repeat in
yeast opens the possibility for the use of genetic screens to
unravel its mode of action.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Compelling evidence places ubiquitin/proteasome-depen-
dent proteolysis at the heart of a plethora of essential cellular
functions. The degradation machinery acts via a two-step pro-
cess. The substrates are ¢rst tagged with a high molecular
weight ubiquitin chain that is generated by the sequential
action of a ubiquitin activase (E1), ubiquitin conjugases
(E2), and ubiquitin ligases (E3) [1]. In addition, the require-
ment for a ubiquitin elongation factor (E4) has been docu-
mented for some substrates [2,3]. The E1 activates the car-
boxy-terminus of ubiquitin through the formation of a
thiolester bond between an active cysteine residue and the
C-terminal glycine residue of ubiquitin. Through the com-
bined action of E2s and E3s, the C-terminus of ubiquitin is
then transferred to the O-NH3 group of a lysine residue within
the substrate. In the subsequent steps the conjugated ubiquitin
becomes itself ubiquitinated at Lys48 or, more rarely, Lys29
residues, which, through successive rounds of ubiquitination,
results in the formation of a polyubiquitin chain. The poly-
ubiquitinated substrates are subsequently recruited to a large
proteolytic complex, the proteasome, where they are deubiqui-
tinated, unfolded, translocated into the cavity harbouring the
proteolytic sites, and processively degraded into small peptide
fragments [4].
Identi¢cation of the signals that determine the rate of turn-
over of speci¢c substrates and elucidation of their mode of
action are prime goals for understanding the regulation of
cellular functions by ubiquitin/proteasome-dependent proteol-
ysis. It is well established that substrates carry degradation
signals [5], also known as degrons [6], which directly or indi-
rectly facilitate interaction with the E3s [7]. These degradation
signals can be short amino acid motifs, globular domains,
misfolded protein structures or even oligosaccharide chains
[5,8,9]. While some degradation signals are constitutively ac-
tive others are positively or negatively regulated through var-
ious posttranslational modi¢cations [5,10^12]. Although a
multitude of di¡erent interactions may be generated through
these structures and their modi¢cation, it seems unlikely that
degradation signals would be the only determinants of protein
half-life. We have recently postulated that proteins may also
harbour stabilisation signals that block or delay proteasomal
degradation [13]. A repetitive sequence present in the Epstein^
Barr virus (EBV) nuclear antigen (EBNA)-1 ful¢ls the criteria
for this type of regulatory element [14].
EBNA-1 contains a repetitive domain composed solely of
glycine and alanine residues that varies in lengths from 60 to
more than 300 amino acids in di¡erent virus isolates [15]. The
glycine-alanine (GA) repeat blocks proteasomal degradation
of EBNA-1 [16], which prevents the elimination of the latent
viral reservoir by cytotoxic T cells [17]. Interestingly, the GA
repeat can also speci¢cally retard or abrogate the degradation
of other proteasomal substrates expressed as arti¢cial fusions
proteins [18]. Functional GA repeat chimeras have been made
for the inhibitor of NF-UB, IUB-K [19], and the tumour sup-
pressor p53 [20]. Although analogous stabilisation signals
have not yet been identi¢ed in cellular proteins, a glycine-
rich region (GRR) in the NF-UB precursor p105 shares
some similarities with the viral repeat in that its presence
de¢nes the site of proteasomal processing and protects the
product from complete degradation [21]. Intriguingly, two
yeast membrane transcription factors that are distant homo-
logues of the NF-UB precursor and similarly subject to pro-
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teasome-dependent processing contain low complexity sequen-
ces located at a position corresponding to the GRR [22].
While the precise mode of action of the GA repeat remains
elusive, biochemical and cellular studies have narrowed the
range of possible targets. We have shown that GA repeat-
containing chimeras are e⁄ciently ubiquitinated but fail to
establish stable interactions with the proteasome in vivo
[16,19], although they can still interact with S5a, a polyubiq-
uitin binding subunit of the proteasome, in vitro [20]. Fur-
thermore, while the GA repeat has exclusively cis-stabilising
activity in vivo [19,20], a synthetic GA repeat peptide was able
to trans-inhibit proteasomal degradation in vitro without af-
fecting ubiquitination and while preserving the interaction of
the ubiquitinated substrate with S5a [23]. Together these data
suggest that the GA repeat and related motifs may a¡ect a
critical step in the recognition of ubiquitinated proteins by the
proteasome, perhaps by triggering the release of the substrate
prior to degradation or, as in the case of the GRR, after
partial processing. Characterisation of this putative substrate
recognition step and identi¢cation of its molecular compo-
nents could help explain the e¡ect of the viral repeat and
may have important implications for the general mode of
action of the postulated cellular stabilisation signals.
In this investigation we have addressed these questions by
asking whether the mechanism targeted by the GA repeat is
evolutionarily conserved. Using arti¢cial green £uorescent
protein (GFP)-based proteasomal substrates containing re-
combinant yeast codon-optimised GA repeats of di¡erent
length, we show that the repeat stabilises N-end rule and
ubiquitin fusion degradation (UFD) substrates in Saccharo-
myces cerevisiae. The demonstration that the activity of the
GA repeat is conserved in yeast now allows a genetic ap-
proach to the analysis of its mechanism of action.
2. Materials and methods
2.1. Yeast strains and plasmids
All strains are derivatives of DF5 (lys2-801, leu2-3, -112, ura3-52,
his3-v200, trp1-1) [24]. The ubr1v, ubc4/ubc5v, ufd2v, ufd4v, and
mcb1v strains have been described previously [25^28]. The Ub-M-
GFP, Ub-R-GFP and UbG76V-GFP without and with the EBV
GA239 [29] were excised with EcoRI and NotI and cloned in
pYES2 (Invitrogen) under the regulation of the galactose-inducible
GAL1 promoter.
2.2. Generation of the recombinant GA repeat
The recombinant GA (rGA) repeat was generated by annealing
complementary DNA oligonucleotides encoding the octamer GGA-
GAGAG at 75‡C for 1 h. The sequence of the sense rGA repeat oligo
was 5P-GG GTG TAC AGA TCT GGT GGT GCT GGT GCT GGT
GCT GGA TCC CTG TAC AGG G-3P (SspBI sites, italic; BglII site,
underline; repeat encoding, bold; BamHI, double underline) (Sigma-
Genosys). The annealed oligos were digested with SspBI. The Ub-M
encoding part (including the 5P BglII and BamHI sites) was removed
from Ub-M-GFP by religating the vector after BglII/BamHI digestion
resulting in GFP(vUb-X). The SspBI-digested double-stranded oligo-
nucleotides were cloned into the unique SspBI site of GFP(vUb-X).
By successive excision of the repeat from the vector with BglII and
BamHI followed by insertion in the unique BamHI site the GFP(vUb-
X)-rGA26 (double insertion), GFP(vUb-X)-rGA53, GFP(vUb-X)-
rGA107 and GFP(vUb-X)-rGA215 were generated (see Fig. 3). The
GFP-rGA fragments were excised with PinAI and NotI and used to
replace the GFP in the pYES2 Ub-M-GFP, Ub-R-GFP and UbG76V-
GFP plasmids giving rise to their repeat containing counterparts.
2.3. Flow cytometry
Yeast transformed with pYES2 plasmids encoding various Ub-X-
GFP fusions were grown successively in medium with glucose, ra⁄-
nose and galactose as sole carbohydrate source, and then in galactose
until midlog phase. The induced cultures were analysed with a FAC-
Sort £ow cytometer (Becton-Dickinson). The mean £uorescence inten-
sity of yeast transformed with empty pYES2 was subtracted from
mean £uorescence intensities of GFP fusion-expressing yeast.
2.4. Western blot analysis
Expression from the GAL1 promoter was induced as described
above. Total protein extracts of cultures in midlog phase were ob-
tained by lysis in 1.85 M NaOH and precipitation in 50% trichloro-
acetic acid [30]. Protein extracts corresponding to 0.25 OD600 units
were resolved by sodium dodecyl sulfate^polyacrylamide gel electro-
phoresis (SDS^PAGE) and transferred to nitrocellulose membranes
(Schleicher and Schuell, Keene, NH, USA). The membranes were in-
cubated with a mix of two monoclonal anti-GFP antibodies (Roche),
followed by incubation with a horseradish peroxidase-labelled second-
ary anti-mouse antibody. Immunocomplexes were visualised using
enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech).
2.5. Pulse chase analysis
Induced midlog-phase yeast cultures were washed once in medium
lacking methionine and metabolically labelled for 10 min in medium
containing 35S-labelled methionine (Amersham Pharmacia Biotech).
An excess of cold methionine was then added and aliquots corre-
sponding to 3 OD600 units were taken at the indicated time points.
The yeast was lysed in HEPES lysis bu¡er (50 mM HEPES, 5 mM
EDTA, 1% Triton X-100, 150 mM NaCl), supplemented with 20 mM
N-ethylmaleimide (Sigma-Aldrich) using acid-washed glass beads (Sig-
ma-Aldrich). Crude extracts were precleared overnight with protein
A-Sepharose (CL-4B, Amersham Pharmacia Biotech). After incuba-
tion with a rabbit polyclonal anti-GFP serum (Molecular Probes), the
protein^antibody complexes were precipitated for 3 h at 4‡C with
protein A-Sepharose beads and washed extensively in ice-cold lysis
bu¡er. The beads were dissolved in loading bu¡er and the proteins
were denatured by boiling before separation by SDS^PAGE. The gel
was dried and exposed to a phospho-imager screen, followed by quan-
ti¢cation of the radioactive signal using a phospho-imager (Molecular
Dynamics) and the ImageQuant software program (Molecular Dy-
namics).
3. Results
3.1. Generation of £uorescent reporters for ubiquitin-dependent
proteolysis in yeast
We have previously described the production of GFP-based
proteasome substrates for functional analysis of the ubiquitin/
proteasome system in mammalian cells [31,32]. To investigate
the functionality of these £uorescent reporters in S. cerevisiae,
the stable Ub-M-GFP, the N-end rule substrate Ub-R-GFP
and the UFD substrate UbG76V-GFP were expressed from the
GAL1 promoter (Fig. 1A). Flow cytometric analysis of wild
type yeast expressing the di¡erent ubiquitin^GFP fusions
showed high £uorescent intensities of yeast expressing the
Ub-M-GFP while the expression of Ub-R-GFP and UbG76V-
GFP resulted in £uorescent intensities close to the back-
ground levels of yeast transformed with an empty plasmid
(Fig. 1B, left panel).
Degradation of the N-end rule substrates in yeast depends
on the RING ¢nger-containing E3 ligase Ubr1 [33], while
UFD substrates are recognised and ubiquitinated by the
HECT (homologous to E6-AP C-terminus) domain E3 ligase
UFD4 [26]. In addition, degradation of UFD substrates but
not N-end rule substrates depends on the activity of the E2
ubiquitin conjugases UBC4 or UBC5 [28], and the recently
identi¢ed E4 ubiquitin elongation factor UFD2 [2]. In order
to investigate whether the GFP reporters are targeted through
the anticipated pathways, we analysed the £uorescent inten-
sities of the yeast mutants ubr1v, ubc4/ubc5v, ufd4v, and
ufd2v. As expected, the Ub-R-GFP reporter was stabilised
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in the ubr1v strain, resulting in £uorescent intensities compa-
rable to those observed with the stable Ub-M-GFP while the
£uorescence remained at background levels in ubr1v express-
ing UbG76V-GFP (Fig. 1B,C). Conversely, UbG76V-GFP gave
increased £uorescence intensities in the ubc4/ubc5v, ufd4v
and ufd2v mutants (Fig. 1C), although the £uorescent inten-
sity did not reach the levels achieved with the stable Ub-M-
GFP. The ubc4/ubc5v double mutant reached the same £uo-
rescent intensity of the E4 ufd2v mutant while deletion of the
E3 UFD4 had a stronger stabilising e¡ect (Fig. 1C). As ex-
pected, the Ub-R-GFP did not show increased £uorescence in
these mutants. Together, these data con¢rm that independent
ubiquitination pathways target the Ub-R-GFP and UbG76V-
GFP reporters.
3.2. The GA repeat inhibits ubiquitin-dependent proteolysis in
yeast
In order to investigate the e¡ect of the EBV GA repeat in
yeasts, the 239-amino acid repeat of the prototype B95.8 EBV
strain [34] was inserted at the C-terminus of the Ub-M-GFP
and Ub-R-GFP reporters. Unexpectedly, insertion of the re-
peat resulted in a strong reduction in the steady-state levels of
Fig. 1. Characterisation of N-end rule and UFD GFP substrates in yeast. A: Schematic drawing of the ubiquitin^GFP fusions. The linker ami-
no acid sequences of the stable Ub-M-GFP, the N-end rule Ub-R-GFP and the UFD UbG76V-GFP constructs are depicted. B: Flow cytometric
analysis of the GFP levels in wild type yeast and ubr1v mutant transformed with Ub-M-GFP, Ub-R-GFP and UbG76V-GFP. C: Quanti¢cation
of the relative £uorescence intensities of wild type and mutant yeast strains transformed with Ub-M-GFP, Ub-R-GFP and UbG76V-GFP con-
structs. Mean £uorescence intensities were measured with £ow cytometry and standardised with Ub-M-GFP in the corresponding strain as
100%.
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both the stable Ub-M-GFP (Fig. 2, upper panel) and the
unstable Ub-R-GFP reporter in the ubr1v mutant (Fig. 2,
lower panel). A small but reproducible increase in £uorescence
was observed with the Ub-R-GFP-GA compared to Ub-R-
GFP in wild type yeast in line with a possible stabilising e¡ect
of the repeat (Fig. 2, middle panel).
The low £uorescence of the stable Ub-M-GFP-GA suggests
that insertion of the viral sequence may directly a¡ect the
expression of the fusion protein, thereby masking the e¡ect
of the repeat. Indeed, the glycine residues in the EBV repeat
are encoded by GGG or GGA codons and the alanine by
the GCA codon, which have a low usage frequency (11,
21 and 11%, respectively) in highly expressed yeast genes
(ftp://genome-ftp.stanford.edu/pub/codon/ysc.gene.cod). To test
whether the GA codon usage may in£uence expression, we
used a sequential cloning strategy to generate a rGA repeat
with a yeast codon-optimised sequence (Fig. 3A,B). In this
repeat, the glycine and alanine residues are encoded by high
frequency GGT (49%) and GCT (38%) codons, respectively.
The rGA contains multiple copies of the minimal repeat that
was shown to be protective in mammalian cells, Gly-Gly-Ala-
Gly-Ala-Gly-Ala-Gly [19], interspersed by single serine resi-
dues that were introduced for cloning purposes. The serine
residues are not present in the EBV repeat but are found in
the repeats of EBNA-1 homologues from primate viruses [35].
In order to validate the recombinant sequences, rGA repeats
of 53, 107 and 215 amino acids were ¢rst checked for their
capacity to reproduce the e¡ect of the viral GA repeat in
mammalian cells. HeLa cells were transiently transfected
with Ub-M-GFP and Ub-R-GFP carrying no repeat,
rGA215 or EBV GA239 and expression was monitored by
Western blot (Fig. 4A) or transfected cells were treated with
proteasome inhibitor and analysed by £ow cytometry
(Fig. 4B). In accordance with previous results [29], treatment
of Ub-R-GFP-transfected cells with 10 WM Z-L3-VS induced
Fig. 2. Expression of EBV GA repeat fusions in yeast. Flow cytometric analyses of wild type and ubr1v mutant yeast expressing Ub-M-GFP
and Ub-R-GFP with and without the EBV GA repeat of 239 amino acids.
Fig. 3. Generation of yeast codon-optimised rGA repeat. A: Sche-
matic presentation of the cloning strategy for the generation of a
yeast codon-optimised rGA repeat. B: Amino acid sequences of the
EBV GA239 and the rGA repeats.
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a clear increase in the percentage of £uorescent cells (Fig. 4B).
Insertion of either the rGA215 or the EBV GA239 resulted in
increased steady-state levels of Ub-R-GFP and a high per-
centage of £uorescent cells with minimal further increase
upon inhibition of the proteasome (Fig. 4A,B). Although
complete protection was not achieved, the comparable ratio
of £uorescent cells in the absence and presence of inhibitor
con¢rms that the EBV GA239 and the rGA repeats are
equally capable of blocking proteasomal degradation in mam-
malian cells (Fig. 4C).
In agreement with the possibility that the low expression of
the fusion proteins containing the viral GA repeat was pri-
marily due to poor synthesis, Ub-M-GFP fusions containing
the yeast codon-optimised repeats rGA53, rGA107, rGA215
were clearly detected in yeast although a rGA length-depen-
dent decrease in the expression levels of the chimeras was still
observed (Fig. 5A). We then analysed the £uorescence inten-
sities of yeast expressing Ub-R-GFP and UbG76V-GFP with
and without rGA repeats. Representative £uorescence histo-
grams of yeast cells expressing Ub-R-GFP with and without
the rGA are shown in Fig. 5B and the summary of results
obtained in three independent experiments performed with
each construct is shown in Fig. 5C. To compensate for the
length-dependent decrease in the steady-state levels, the data
in Fig. 5C were normalised to the £uorescence intensity of
yeast expressing Ub-M-GFP fusions containing the same re-
Fig. 4. The rGA repeat is functional in mammalian cells. A: HeLa
cells were transiently transfected with Ub-M-GFP or Ub-R-GFP
without repeat or with the rGA107 or rGA215. Lysates were
analysed by Western blotting using a polyclonal GFP antibody.
B: Transiently transfected HeLa cells were incubated with 10 WM of
the proteasome inhibitor Z-L3-VS or left untreated. Ten hours after
administration of the inhibitor the cells were harvested and analysed
by £ow cytometry. The percentage of GFP-positive cells is indicated
in the upper left corner. C: Quantitative analysis of £ow cytometric
analysis as depicted in B. Relative £uorescence is expressed as the
percentage of GFP-positive cells in the absence of inhibitor divided
by the percentage of GFP-positive cells in the presence of inhibitor.
Values are mean and standard deviations of three independent ex-
periments. Values signi¢cantly di¡erent from Ub-R-GFP are indi-
cated with an asterisk (t-test, P6 0.01).
Fig. 5. Expression of rGA fusions in yeast. A: Expression of the in-
dicated Ub-M-GFP-rGA fusions was induced in wild type yeast.
Lysates were analysed by Western blot analysis with a polyclonal
anti-GFP antibody. B: Representative £ow cytometry analyses illus-
trating the stabilising e¡ect of the rGA on Ub-R-GFP. Mean £uo-
rescence intensities are indicated in the upper right corner of each
histogram. C: Relative £uorescence intensities of yeast expressing
the indicated Ub-R-GFP-rGA and UbG76V-GFP-rGA fusions. The
relative £uorescence was calculated by dividing the mean £uores-
cence intensity of Ub-R-GFP-rGA and UbG76V-GFP-rGA fusion-ex-
pressing yeast by the mean £uorescence intensity of yeast expressing
the Ub-M-GFP-rGA with the same repeat length. Values are mean
and standard deviations of three independent experiments. Values
signi¢cantly di¡erent from the control Ub-R-GFP and UbG76V-GFP
lacking the repeats are indicated with one asterisk (t-test, P6 0.05)
or two asterisks (t-test, P6 0.01).
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peat. Both Ub-R-GFP-rGA and UbG76V-GFP-rGA were ex-
pressed at signi¢cantly higher levels compared to their repeat-
less counterparts.
In order to test if the increased steady-state levels were in-
deed due to inhibition of ubiquitin-dependent proteolysis, the
degradation of the chimeras was monitored in pulse chase
experiments. The half-life of Ub-R-GFP was approximately
5 min, while introduction of the rGA107 or rGA215 resulted
in half-lives of over 20 min (Fig. 6A,B). Furthermore, inser-
tion of the rGA53 prolonged the half-life of UbG76V-GFP
from approximately 20 min to full stabilisation within the
analysed time interval (Fig. 6C,D). These data show that
the rGA repeat can inhibit ubiquitin-dependent proteasomal
degradation of N-end rule and UFD substrates in S. cerevi-
siae.
3.3. The protective e¡ect of the rGA does not require the
polyubiquitination binding subunit Rpn10
Previous studies have demonstrated that the GA repeat
does not a¡ect the ubiquitination of proteasomal substrates
[20] and ubiquitinated p53-GA chimeras maintain the capacity
to interact with the polyubiquitin binding proteasome subunit
S5a [18]. The vast majority of the cellular S5a is not in com-
plex with the proteasome in yeast [36], which prompted us to
test whether sequestration of the polyubiquitinated GA re-
peat-containing proteins could be of importance for the pro-
tective e¡ect. Deletion of the yeast S5a homologue, Rpn10,
results in stabilisation of UFD substrates while degradation of
N-end rule substrates is una¡ected [27]. We therefore com-
pared the degradation of Ub-R-GFP and Ub-R-GFP-
rGA107 in wild type yeast and rpn10v strain in a promoter
shut-o¡ experiment. Ub-R-GFP was e⁄ciently degraded
in the absence of Rpn10 while the rGA-containing chimera
was stable in the mutant (Fig. 7). Thus, the Rpn10 protein
is not required for the protective e¡ect of the repeat in
yeast.
4. Discussion
In this study we have shown that the ubiquitin-dependent
proteolysis of two GFP-based proteasome substrates in
S. cerevisiae can be blocked by introduction of a designed
rGA repeat that resembles the wild type repeat found in
EBV isolates. Analysis of the degradation of UFD- and
N-end rule-targeted GFP in wild type and mutant yeasts con-
¢rmed that these substrates are targeted through di¡erent
ubiquitination pathways. Interestingly the UbG76V-GFP re-
porter was only partially stabilised in UFD deletion mutant
yeasts. The UFD substrates are targeted via conjugation of
separate ubiquitin chains to Lys29 and Lys48 of the N-termi-
nal ubiquitin moiety [26]. The E2s, E3 and E4 of the pathway,
UBC4/UBC5, UFD4 and E4, respectively, are di¡erently in-
volved in the formation of these two trees. Speci¢cally, UBC4/
UBC5 and UFD4 are important for the formation of the
Lys29 tree [26], while UFD2 elongates Lys48 ubiquitin trees
[2]. We have previously shown that, in contrast to previously
characterised UFD substrates that require the Lys29 tree or
both trees [26], UbG76V-GFP substrate can be targeted in
mammalian cells independently by Lys29 or Lys48 polyubiq-
uitin trees [37]. Hence, the partial stabilisation observed in
these mutants may be due to the fact that only a single ubiq-
uitin tree is a¡ected in each of these mutants while the remain-
ing tree can still trigger degradation of UbG76V-GFP.
The protective e¡ect the rGA in yeast can be explained in
two ways. The GA repeat may function as an autonomous
element in a manner similar to the polyglutamine repeats
found in neurodegenerative disorders, which stabilise proteins
through the formation of macromolecular aggregates [38].
Alternatively, the GA repeat may target a conserved step in
the proteolytic pathway that is present in both yeast and high-
er eukaryotes. Although we cannot formally exclude the pos-
sibility that the rGA may induce the formation of submicro-
Fig. 6. The rGA repeat protects N-end rule and UFD substrates
from proteasomal degradation. Expression of Ub-R-GFP and
UbG76V-GFP without or with rGA repeats was induced in wild type
yeast and their turnover was determined by pulse chase analysis.
Yeast was labelled for 10 min with [35S]Met and subsequently incu-
bated for the indicated time points with an excess of unlabelled
Met. A: Autoradiograms of pulse chase analysis of yeast expressing
Ub-R-GFP (upper panel), Ub-R-GFP-rGA107 (middle panel) and
Ub-R-GFP-rGA215 (lower panel). B: Densitometric quanti¢cation
of the autoradiogram shown in A. C: Autoradiograms of pulse
chase analysis of yeast expressing UbG76V-GFP (upper panel) and
UbG76V-GFP-rGA53 (lower panel). D: Densitometric quanti¢cation
of the autoradiogram shown in B. One representative experiment
out of three.
Fig. 7. Rpn10 is not required for the protective e¡ect of the rGA
repeat. Expression of Ub-R-GFP and Ub-R-GFP-rGA107 was in-
duced in wild type yeast and the rpn10v strain. The GAL1 pro-
moter was shut o¡ by changing from galactose to glucose as a car-
bon source in combination with addition of cycloheximide to block
translation after which the degradation of the GFP fusion was fol-
lowed. Western blot analysis of Ub-R-GFP and Ub-R-GFP-rGA107
in wild type and rpn10v strain after promoter shut o¡.
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scopic aggregates in yeasts, data from earlier studies in mam-
malian cells strongly support the second model. Structural
analysis of an IUB-K-GA repeat chimera revealed a £exible
structure for the inserted repeat [39]. Moreover, microscopic
examination of cells expressing GFP-GA fusions did not re-
veal macromolecular aggregates of the type observed in cells
expressing extended polyglutamine repeat-containing proteins
[29]. In several model systems we have shown that the pro-
tective e¡ect of the viral repeat is restricted to the harbouring
protein and does not hinder proteasomal degradation of other
substrates [19,20]. In contrast, polyglutamine proteins and
other designed proteins with stable domains cause a general
obstruction of proteasomal degradation, which is presumably
caused by choking the proteasome with indigestible stable
substrates [40]. The most striking evidence against the possi-
bility that the GA repeat may act as an autonomous element
comes from the in vitro degradation of model substrates
where a short soluble GA repeat peptide can e⁄ciently block
ubiquitin-dependent proteolysis in a dose-dependent manner
without a¡ecting the enzymatic activity of the proteasome
[23].
The demonstration that the GA repeat retains its inhibitory
activity in yeast opens the possibility for a detailed molecular
analysis of its mechanism of action based on the use of yeast
mutants. We have earlier shown that, while the polyubiquiti-
nated GA repeat-containing proteins fail to establish a stable
interaction with the proteasome [19], they were still capable of
interacting with the polyubiquitin binding subunit S5a/Rpn10
[20]. Since a large fraction of the intracellular S5a/Rpn10 is
not in complex with the 19S cap of the proteasome [27,36],
interaction with free S5a may preclude the recruitment of the
substrate to the proteasome. Using a yeast Rpn10 deletion
mutant, we have now conclusively demonstrated that interac-
tion with this component of the ubiquitin^proteasome path-
way is not required for the protective e¡ect of the repeat.
The mammalian transcription factor NF-UB [41] and the
related yeast proteins STP23 and MGA2 [42] are activated
by partial proteasomal processing of their precursors. It has
been postulated that the GRR domain that drives the process-
ing of NF-UB may share some similarity with the EBV GA
repeat [21]. The low complexity sequences present in NF-UB,
STP23 and MGA2 may allow the formation of a £exible loop
that is required for endoproteolytic processing of the substrate
by the proteasome [22]. The GA motif contained within the
GRR may further protect the part of the precursor that ‘es-
capes’ from degradation. In line with this scenario, the low
complexity sequence resides on the product part of each of
these precursor proteins. However, Sears and co-workers have
reported that, while the NF-UB precursor is correctly pro-
cessed in yeast, processing becomes independent of the
GRR [43]. This suggests that subtle di¡erences may exist in
the mode of action between the repeats in mammalian and
yeast cells.
We have previously postulated that the turnover of sub-
strates of the ubiquitin/proteasome system may be determined
by the balance between degradation signals, which target pro-
teins for ubiquitination, and stabilisation signals that counter
the degradation signals either by reversing the ubiquitination
of proteins or by modifying a post-ubiquitination step [13].
The evidence present in this study is in line with the idea that
such stabilisation signals are ancient regulatory elements that
modulate ubiquitin/proteasome-dependent proteolysis.
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